{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:51:36Z","timestamp":1791154296908,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["5R01AG068450"],"award-info":[{"award-number":["5R01AG068450"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s11606-026-10631-z","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T18:19:29Z","timestamp":1784571569000},"page":"3790-3798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effectiveness of Antidepressants and Second-Generation Antipsychotics for Agitation Among Nursing Home Residents with Dementia"],"prefix":"10.1007","volume":"41","author":[{"given":"Shiwei","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate L.","family":"Lapane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Tjia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonggyu","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5604-721X","authenticated-orcid":false,"given":"Matthew","family":"Alcusky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"5","key":"10631_CR1","first-page":"3708","volume":"20","author":"Alzheimer's disease facts and figures","year":"2025","unstructured":"2025 Alzheimer's disease facts and figures. Alzheimers Dement. 2025;20(5):3708\u20133821.","journal-title":"Alzheimers Dement."},{"key":"10631_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fneur.2012.00073","volume":"3","author":"J Cerejeira","year":"2012","unstructured":"Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.","journal-title":"Front Neurol."},{"issue":"5","key":"10631_CR3","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","volume":"7","author":"CG Lyketsos","year":"2011","unstructured":"Lyketsos CG, et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement. 2011;7(5):532\u20139.","journal-title":"Alzheimers Dement."},{"key":"10631_CR4","doi-asserted-by":"crossref","unstructured":"Crystal S, et al. National Partnership to Improve Dementia Care in Nursing Homes Campaign: State and Facility Strategies, Impact, and Antipsychotic Reduction Outcomes. Innov Aging. 2020;4(3):igaa018.","DOI":"10.1093\/geroni\/igaa018"},{"issue":"5","key":"10631_CR5","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","volume":"72","author":"DT Maust","year":"2015","unstructured":"Maust DT, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatr. 2015;72(5):438\u201345.","journal-title":"JAMA Psychiatr."},{"issue":"4","key":"10631_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.amjopharm.2008.10.002","volume":"6","author":"P Kamble","year":"2008","unstructured":"Kamble P, et al. Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother. 2008;6(4):187\u201397.","journal-title":"Am J Geriatr Pharmacother."},{"key":"10631_CR7","unstructured":"Muhlbauer V, et al. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2021;12(12):CD013304."},{"issue":"4","key":"10631_CR8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.14283\/jpad.2021.48","volume":"8","author":"I Yunusa","year":"2021","unstructured":"Yunusa I, et al., Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review. J Prev Alzheimers Dis. 2021;8(4):520\u2013533.","journal-title":"J Prev Alzheimers Dis."},{"issue":"1","key":"10631_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40266-022-00992-5","volume":"40","author":"M Rogowska","year":"2023","unstructured":"Rogowska M, et al. Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update. Drugs Aging. 2023;40(1):21\u201332.","journal-title":"Drugs Aging."},{"key":"10631_CR10","unstructured":"Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. 2005 [cited 2024 Jan 11th]; Available from: https:\/\/wayback.archive-it.org\/7993\/20170113112252\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm053171.htm."},{"key":"10631_CR11","unstructured":"Information for Healthcare Professionals: Conventional Antipsychotics. 2008 [cited 2024 Jan 11th]; Available from: https:\/\/wayback.archive-it.org\/7993\/20170722190727\/https:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124830.htm."},{"issue":"5","key":"10631_CR12","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1001\/jamainternmed.2018.0379","volume":"178","author":"DT Maust","year":"2018","unstructured":"Maust DT, et al., Association of the Centers for Medicare & Medicaid Services' National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014. JAMA Intern Med. 2018;178(5):640\u2013647.","journal-title":"JAMA Intern Med."},{"issue":"12","key":"10631_CR13","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1111\/jgs.18004","volume":"70","author":"AB Coe","year":"2022","unstructured":"Coe AB, et al., Psychotropic medication prescribing in assisted living and nursing home residents with dementia after the National Partnership. J Am Geriatr Soc. 2022;70(12):3513\u20133525.","journal-title":"J Am Geriatr Soc."},{"issue":"4","key":"10631_CR14","doi-asserted-by":"publisher","first-page":"e203630","DOI":"10.1001\/jamanetworkopen.2020.3630","volume":"3","author":"A Rubino","year":"2020","unstructured":"Rubino A, et al. Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia. JAMA Netw Open. 2020;3(4):e203630.","journal-title":"JAMA Netw Open."},{"key":"10631_CR15","unstructured":"Liang S, et al., Antidepressant Use Among US Nursing Home Residents with Dementia in 2018 [Under Review]. J Am Geriatr Soc. 2025."},{"issue":"1","key":"10631_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13195-021-00867-8","volume":"13","author":"M Seibert","year":"2021","unstructured":"Seibert M, et al. Efficacy and safety of pharmacotherapy for Alzheimer's disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials. Alzheimers Res Ther. 2021;13(1):131.","journal-title":"Alzheimers Res Ther."},{"issue":"3","key":"10631_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1533317511402051","volume":"26","author":"G Henry","year":"2011","unstructured":"Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26(3):169\u201383.","journal-title":"Am J Alzheimers Dis Other Demen."},{"issue":"11","key":"10631_CR18","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1097\/JGP.0b013e3180cc1ff5","volume":"15","author":"BG Pollock","year":"2007","unstructured":"Pollock BG, et al., A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatr. 2007;15(11):942\u201352.","journal-title":"Am J Geriatr Psychiatr."},{"key":"10631_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0167-4943(01)00135-2","volume":"7","author":"S Gaber","year":"2001","unstructured":"Gaber S, et al., Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia. Arch Gerontol Geriatr Suppl. 2001;7:159\u201362.","journal-title":"Arch Gerontol Geriatr Suppl."},{"issue":"9","key":"10631_CR20","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1212\/WNL.55.9.1271","volume":"55","author":"L Teri","year":"2000","unstructured":"Teri L, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55(9):1271\u20138.","journal-title":"Neurology."},{"issue":"1","key":"10631_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00019442-199705010-00008","volume":"5","author":"DL Sultzer","year":"1997","unstructured":"Sultzer DL, et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatr. 1997;5(1):60\u20139.","journal-title":"Am J Geriatr Psychiatr."},{"key":"10631_CR22","doi-asserted-by":"crossref","unstructured":"Seitz DP, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2):CD008191.","DOI":"10.1002\/14651858.CD008191.pub2"},{"issue":"7","key":"10631_CR23","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1111\/bcp.13604","volume":"84","author":"K Kongpakwattana","year":"2018","unstructured":"Kongpakwattana K, et al. Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis. Br J Clin Pharmacol. 2018;84(7):1445\u20131456.","journal-title":"Br J Clin Pharmacol."},{"issue":"4","key":"10631_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol."},{"issue":"6","key":"10631_CR25","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/gerona\/glab373","volume":"77","author":"EP McCarthy","year":"2022","unstructured":"McCarthy EP, et al. Validation of Claims Algorithms to Identify Alzheimer's Disease and Related Dementias. J Gerontol A Biol Sci Med Sci. 2022;77(6):1261\u20131271.","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"12","key":"10631_CR26","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jamda.2019.08.030","volume":"20","author":"E McCreedy","year":"2019","unstructured":"McCreedy E, et al. The Minimum Data Set Agitated and Reactive Behavior Scale: Measuring Behaviors in Nursing Home Residents With Dementia. J Am Med Dir Assoc. 2019;20(12):1548\u20131552.","journal-title":"J Am Med Dir Assoc."},{"key":"10631_CR27","doi-asserted-by":"crossref","unstructured":"Gerlach LB, et al. Trends in Antipsychotic and Mood Stabilizer Prescribing in Long-Term Care in the U.S.: 2011\u20132014. J Am Med Dir Assoc. 2020;21(11):1629\u20131635.e8.","DOI":"10.1016\/j.jamda.2020.05.039"},{"issue":"8","key":"10631_CR28","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/gps.2607","volume":"26","author":"R Howard","year":"2011","unstructured":"Howard R, et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. Int J Geriatr Psychiatr. 2011;26(8):812\u20137.","journal-title":"Int J Geriatr Psychiatr."},{"key":"10631_CR29","doi-asserted-by":"crossref","unstructured":"Thomas KS, et al. The Minimum Data Set 3.0 Cognitive Function Scale. Med Care. 2017;55(9):e68\u2013e72.","DOI":"10.1097\/MLR.0000000000000334"},{"key":"10631_CR30","doi-asserted-by":"crossref","unstructured":"Saliba D, et al. MDS 3.0: brief interview for mental status. J Am Med Dir Assoc. 2012;13(7):611\u20137.","DOI":"10.1016\/j.jamda.2012.06.004"},{"issue":"5","key":"10631_CR31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/gps.5074","volume":"34","author":"E Belanger","year":"2019","unstructured":"Belanger E, et al. Measurement validity of the Patient-Health Questionnaire-9 in US nursing home residents. Int J Geriatr Psychiatr. 2019;34(5):700\u2013708.","journal-title":"Int J Geriatr Psychiatr."},{"issue":"11","key":"10631_CR32","doi-asserted-by":"publisher","first-page":"M546","DOI":"10.1093\/gerona\/54.11.M546","volume":"54","author":"JN Morris","year":"1999","unstructured":"Morris JN, Fries BE, Morris SA. Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci. 1999;54(11):M546\u201353.","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"19","key":"10631_CR33","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1002\/sim.5786","volume":"32","author":"F Li","year":"2013","unstructured":"Li F, Zaslavsky AM, Landrum MB. Propensity score weighting with multilevel data. Stat Med. 2013;32(19):3373\u201387.","journal-title":"Stat Med."},{"issue":"521","key":"10631_CR34","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","volume":"113","author":"F Li","year":"2018","unstructured":"Li F, Morgan KL, Zaslavsky AM. Balancing Covariates via Propensity Score Weighting. J Am Stat Assoc. 2018;113(521):390\u2013400.","journal-title":"J Am Stat Assoc."},{"key":"10631_CR35","doi-asserted-by":"publisher","first-page":"1103039","DOI":"10.3389\/fnagi.2023.1103039","volume":"15","author":"K Chen","year":"2023","unstructured":"Chen K, et al. Comparative efficacy and safety of antidepressant therapy for the agitation of dementia: A systematic review and network meta-analysis. Front Aging Neurosci. 2023;15:1103039.","journal-title":"Front Aging Neurosci."},{"issue":"7","key":"10631_CR36","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"AP Porsteinsson","year":"2014","unstructured":"Porsteinsson AP, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682\u201391.","journal-title":"JAMA."},{"key":"10631_CR37","doi-asserted-by":"crossref","unstructured":"Liu KY, et al. Pharmacological treatment trials of agitation in Alzheimer's disease: A systematic review of ClinicalTrials.gov registered trials. Alzheimers Dement (N Y). 2021;7(1):e12157.","DOI":"10.1002\/trc2.12157"},{"key":"10631_CR38","doi-asserted-by":"publisher","first-page":"101362","DOI":"10.1016\/j.arr.2021.101362","volume":"69","author":"TW Hsu","year":"2021","unstructured":"Hsu TW, et al. Efficacy of serotonergic antidepressant treatment for the neuropsychiatric symptoms and agitation in dementia: A systematic review and meta-analysis. Ageing Res Rev. 2021;69:101362.","journal-title":"Ageing Res Rev."},{"issue":"11","key":"10631_CR39","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1002\/alz.14282","volume":"20","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, et al. Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study. Alzheimers Dement. 2024;20(11):8002\u20138011.","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10631_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13670-019-0269-1","volume":"8","author":"CL McDermott","year":"2019","unstructured":"McDermott CL, Gruenewald DA. Pharmacologic Management of Agitation in Patients with Dementia. Curr Geriatr Rep. 2019;8(1):1\u201311.","journal-title":"Curr Geriatr Rep."},{"issue":"1","key":"10631_CR41","first-page":"17","volume":"64","author":"LM Bjerre","year":"2018","unstructured":"Bjerre LM, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(1):17\u201327.","journal-title":"Can Fam Physician."},{"issue":"5","key":"10631_CR42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1176\/appi.ajp.2015.173501","volume":"173","author":"VI Reus","year":"2016","unstructured":"Reus VI, et al. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. Am J Psychiatr. 2016;173(5):543\u20136.","journal-title":"Am J Psychiatr."},{"issue":"1","key":"10631_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1017\/S1041610218000534","volume":"31","author":"HC Kales","year":"2019","unstructured":"Kales HC, et al. Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus. Int Psychogeriatr. 2019;31(1):83\u201390.","journal-title":"Int Psychogeriatr."},{"issue":"10","key":"10631_CR44","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1111\/ene.14412","volume":"27","author":"KS Frederiksen","year":"2020","unstructured":"Frederiksen KS, et al. A European Academy of Neurology guideline on medical management issues in dementia. Eur J Neurol. 2020;27(10):1805\u20131820.","journal-title":"Eur J Neurol."},{"key":"10631_CR45","unstructured":"(NICE), L.N.I.f.H.a.C.E., Dementia: Assessment, management and support for people living with dementia and their carers. 2018: London."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10631-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-026-10631-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-026-10631-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:01:32Z","timestamp":1791151292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-026-10631-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":45,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10631"],"URL":"https:\/\/doi.org\/10.1007\/s11606-026-10631-z","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\u00a0This study was approved by the Institutional Review Board at the University of Massachusetts Chan Medical School (IRB ID: H00020097) and a waiver of informed consent was issued.\u00a0","order":1,"name":"Ethics","label":"Human Ethics and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the National Institute on Aging (Grant: 5R01AG068450).","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}